Related Experiment Video
Updated: Apr 15, 2026

Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum
Published on: December 4, 2015
Chemical attenuation of Plasmodium in the liver modulates severe malaria disease progression
Matthew D Lewis1, Jochen Behrends2, Cláudia Sá E Cunha3
1Centre for Infectious Diseases, Parasitology Unit, Heidelberg University Hospital, D 69120 Heidelberg, Germany; German Centre for Infection Research, D 69120 Heidelberg, Germany;
Abstract:
Cerebral malaria is one of the most severe complications of malaria disease, attributed to a complicated series of immune reactions in the host. The syndrome is marked by inflammatory immune responses, margination of leukocytes, and parasitized erythrocytes in cerebral vessels leading to breakdown of the blood-brain barrier. We show that chemical attenuation of the parasite at the very early, clinically silent liver stage suppresses parasite development, delays the time until parasites establish blood-stage infection, and provokes an altered host immune response, modifying immunopathogenesis and protecting from cerebral disease. The early response is proinflammatory and cell mediated, with increased T cell activation in the liver and spleen, and greater numbers of effector T cells, cytokine-secreting T cells, and proliferating, proinflammatory cytokine-producing T cells. Dendritic cell numbers, T cell activation, and infiltration of CD8(+) T cells to the brain are decreased later in infection, possibly mediated by the anti-inflammatory cytokine IL-10. Strikingly, protection can be transferred to naive animals by adoptive transfer of lymphocytes from the spleen at very early times of infection. Our data suggest that a subpopulation belonging to CD8(+) T cells as early as day 2 postinfection is responsible for protection. These data indicate that liver stage-directed early immune responses can moderate the overall downstream host immune response and modulate severe malaria outcome.
Insights
Chemically attenuating malaria parasites during the silent liver stage alters the immune response, preventing severe cerebral malaria. Early T cell activation protects against disease, transferable via lymphocytes.
Area of Science:
- Immunology
- Parasitology
- Neuroscience
Background:
- Cerebral malaria is a severe complication of malaria, characterized by inflammation and blood-brain barrier breakdown.
- The pathogenesis involves complex host immune reactions, including leukocyte margination and parasitized erythrocyte adhesion.
Purpose of the Study:
- To investigate the impact of early, liver-stage parasite attenuation on cerebral malaria development.
- To understand how this early intervention modifies host immune responses and protects against severe disease.
Main Methods:
- Chemical attenuation of malaria parasites during the liver stage.
- Analysis of host immune responses, including T cell activation, cytokine production, and immune cell infiltration.
- Adoptive transfer of lymphocytes to assess protective immunity.
Main Results:
- Early parasite attenuation suppressed parasite development and delayed blood-stage infection.
- An altered, proinflammatory, cell-mediated immune response was observed, with increased T cell activation and effector cells.
- Protection was transferable via spleen lymphocytes, implicating early CD8(+) T cells.
Conclusions:
- Targeting the liver stage of malaria parasites can significantly alter immunopathogenesis.
- Early immune responses, particularly involving CD8(+) T cells, can prevent severe cerebral malaria.
- Liver-stage interventions offer a promising strategy to modulate downstream immune responses and improve malaria outcomes.
More Related Videos
08:46Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites
Published on: May 18, 2016
08:20In Vitro Assay of Plasmodium-Infected Red Blood Cell Killing by Cytotoxic Lymphocytes
Published on: August 17, 2022
Related Concept Videos
Symbiosis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Diversity of Protists II
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Anthelminthic Agents